0.25
+0.0119(+5.09%)
Currency In USD
| Previous Close | 0.23 |
| Open | 0.23 |
| Day High | 0.25 |
| Day Low | 0.23 |
| 52-Week High | 3.89 |
| 52-Week Low | 0.2 |
| Volume | 551,055 |
| Average Volume | 780,222 |
| Market Cap | 7.81M |
| PE | -0.22 |
| EPS | -1.12 |
| Moving Average 50 Days | 0.37 |
| Moving Average 200 Days | 0.98 |
| Change | 0.01 |
If you invested $1000 in Calidi Biotherapeutics, Inc. (CLDI) since IPO date, it would be worth $2.51 as of July 06, 2025 at a share price of $0.246. Whereas If you bought $1000 worth of Calidi Biotherapeutics, Inc. (CLDI) shares 3 years ago, it would be worth $2.47 as of July 06, 2025 at a share price of $0.246.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Calidi Biotherapeutics Announces Shareholder Letter from CEO
GlobeNewswire Inc.
Jun 27, 2025 12:00 PM GMT
SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the ability to deliver
Calidi Biotherapeutics Presents systemic oncolytic platform with CD55-Enhanced expression and IL-15 Superagonist Payload at ASCO Annual Meeting
GlobeNewswire Inc.
Jun 02, 2025 12:00 PM GMT
SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the ability to deliver
Calidi Biotherapeutics Announces IL15 Superagonist as First Payload to be Delivered by Systemic Antitumor Virotherapy Platform at AACR Annual Meeting
GlobeNewswire Inc.
Apr 28, 2025 12:00 PM GMT
SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the selection of IL1